Potent B-Raf inhibitor (Kd
= 0.3 nM). Selective for B-Raf against 46 other kinases (Ki app
values are 0.16 and 1.72 nM for B-Raf and c-Raf respectively). Decreases anchorage-independent growth of melanoma cell lines. Inhibits ERK phosphorylation and proliferation in tumor cells expressing B-RafV600E
Soluble to 10 mM in DMSO
Store at -20°C
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from GlaxoSmithKline.
Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885.
King et al.
Cancer Res., 2006;66:11100
The identification of potent and selective imidazole-based inhibitors of B-Raf kinase.
Takle et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 590885 include:
Showing Results 1 - 3 of 3